ESR1 and neoplasm: Taken together, these data suggest that in combination therapy, the iGenSig models derived from single-drug treatment data can be confounded by the therapeutic benefits derived from other drugs in the combination, as well as confounding drug resistance factors, such as ER overexpression and late tumor stage.